Xeris Biopharma to proceed with levothyroxine sodium study

Xeris Biopharma announced that, based on feedback from a Type C meeting with the FDA, Xeris will proceed with a Phase II study in patients for its novel formulation of levothyroxine sodium as replacement therapy for hypothyroidism. The company anticipates initiating the study by the second half of 2023.